Medizone International, Inc. (OTCMKTS:MZEI) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On August 25, 2017, Medizone International, Inc. (“Company”) issued a press release announcing the Company’s intention to submit a marketing application to the U.S. Food and Drug Administration (“FDA”) for the use of AsepticSure® as a medical device. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description |
|
99.1 |
Press Release dated August 25, 2017.
|
MEDIZONE INTERNATIONAL INC ExhibitEX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Medizone International Announces Next Steps with FDA on AsepticSure® Medizone International prepares plans to submit a marketing application to FDA for use of AsepticSure as a medical device Kalamazoo,…To view the full exhibit click here
About Medizone International, Inc. (OTCMKTS:MZEI)
Medizone International, Inc. is engaged in designing, manufacturing and selling a system using ozone in the disinfection of surgical and other medical treatment facilities and in other applications. The Company’s AsepticSure is an ozone-based technology, which is used for the purpose of decontaminating and disinfecting hospital surgical suites, emergency rooms, intensive care units and other enclosed spaces, such as gym locker rooms, laboratories and veterinary clinics. In the AsepticSure system, oxygen atoms are misted into the environment with a hydrogen peroxide vapor and the system’s formula creates Trioxidane. The Company is developing a variant of AsepticSure for governmental use with bio-terrorism countermeasures. AsepticSure has completed safety and preliminary operational trials. During the tests, AsepticSure has demonstrated a turnaround time of approximately 90 minutes for disinfection and reoccupation of the hospital rooms.
